<DOC>
	<DOC>NCT02528786</DOC>
	<brief_summary>The purpose of this study is to obtain blood samples from up to 14 subjects who previously received namilumab in the previous study M1-1188-002-EM (PRIORA, [NCT01317797]) to correlate genetic markers with clinical outcomes.</brief_summary>
	<brief_title>Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study.</brief_title>
	<detailed_description>Participants who received treatment with namilumab in the previous study M1-1188-002-EM (PRIORA [NCT01317797]) will have two whole blood samples (3 mL each) collected to correlate genetic markers with namilumab treatment responses as determined in the previous study. The study will enroll approximately 14 participants who received namilumab in the previous study. â€¢ No intervention is administered in this study. This trial will be conducted in Bulgaria, Spain and The Netherlands. The overall time to participate in this study is 1 day.</detailed_description>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>1. The participant (or, when applicable, the participant's legally acceptable representative) voluntarily signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. 1. Did not receive namilumab during the PRIORA study (A phase Ib doubleblind, placebo controlled, randomized, doseescalating study). 2. Participants without any response time point recorded 4week after the last dose of namilumab and beyond this time point 3. Participants who were excluded from posthoc analysis due to protocol violations during the previous PRIORA study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>